Elicio Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $2.3 | $28.3 |
| Operating income | -$37.7 | -$45.0 | -$35.7 | -$23.7 | -$39.3 |
| Net income | -$39.6 | -$51.9 | -$35.2 | -$28.2 | -$54.6 |
| Cash Flow Statement | |||||
| Free cash flow | -$37.0 | -$37.2 | -$32.8 | -$22.8 | -$53.0 |
| Share repurchases | — | $0.0 | $0.1 | $0.0 | — |
Shares outstanding 19.1M · Free float 33.4%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.